Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,178Revenue $M710Net Margin (%)3.9Altman Z-Score2.8
Enterprise Value $M2,279EPS $0.4Operating Margin %5.6Piotroski F-Score3
P/E(ttm)83.1Beneish M-Score-1.4Pre-tax Margin (%)6.7Higher ROA y-yN
Price/Book2.210-y EBITDA Growth Rate %--Quick Ratio2.8Cash flow > EarningsN
Price/Sales3.15-y EBITDA Growth Rate %-2.4Current Ratio3.4Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %19.2ROA % (ttm)1.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)3.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M70.5ROIC % (ttm)2.2Gross Margin Increase y-yN

Gurus Latest Trades with IPXL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
IPXLNWQ Managers 2015-12-31 Reduce-0.21%$34.53 - $44.76
($40.13)
$ 30.89-23%Reduce -66.75%198,378
IPXLNWQ Managers 2015-09-30 Reduce-0.07%$33.27 - $50.42
($45.1)
$ 30.89-32%Reduce -16.00%596,619
IPXLNWQ Managers 2015-06-30 Reduce-0.13%$44.44 - $51.31
($47.45)
$ 30.89-35%Reduce -24.12%710,302
IPXLGeorge Soros 2015-06-30 Sold Out -0.03%$44.44 - $51.31
($47.45)
$ 30.89-35%Sold Out0
IPXLGeorge Soros 2015-03-31 Buy 0.03%$30.2 - $47.3
($39.79)
$ 30.89-22%New holding61,206
IPXLNWQ Managers 2015-03-31 Add0.02%$30.2 - $47.3
($39.79)
$ 30.89-22%Add 3.32%936,127
IPXLJoel Greenblatt 2015-03-31 Sold Out -0.02%$30.2 - $47.3
($39.79)
$ 30.89-22%Sold Out0
IPXLMario Gabelli 2015-03-31 Sold Out -0.0011%$30.2 - $47.3
($39.79)
$ 30.89-22%Sold Out0
IPXLNWQ Managers 2014-12-31 Reduce-0.1%$23.63 - $32.75
($29.3)
$ 30.895%Reduce -30.25%906,043
IPXLJoel Greenblatt 2014-12-31 Add0.01%$23.63 - $32.75
($29.4)
$ 30.895%Add 136.17%79,609
IPXLMario Gabelli 2014-12-31 Buy $23.63 - $32.75
($29.3)
$ 30.895%New holding6,775
IPXLNWQ Managers 2014-09-30 Add0.08%$22.77 - $30.68
($25.55)
$ 30.8921%Add 31.90%1,298,995
IPXLJoel Greenblatt 2014-09-30 Buy 0.01%$22.77 - $30.68
($25.55)
$ 30.8921%New holding33,709
IPXLNWQ Managers 2014-06-30 Buy 0.3%$23.6 - $30.68
($26.93)
$ 30.8915%New holding984,841
IPXLJoel Greenblatt 2012-03-31 Sold Out -0.05%$18.64 - $24.37
($20.72)
$ 30.8949%Sold Out0
IPXLJoel Greenblatt 2011-12-31 Reduce-0.47%$16.53 - $20.75
($18.65)
$ 30.8966%Reduce -88.51%21,057
IPXLJoel Greenblatt 2011-09-30 Reduce-0.38%$15.26 - $21.56
($19.54)
$ 30.8958%Reduce -40.22%183,187
IPXLJoel Greenblatt 2011-06-30 Add0.76%$20.21 - $28.73
($25.28)
$ 30.8922%Add 446.09%306,452
IPXLGeorge Soros 2011-06-30 Sold Out $20.21 - $28.73
($25.28)
$ 30.8922%Sold Out0
IPXLJoel Greenblatt 2011-03-31 Reduce-1.55%$20.11 - $25.52
($22.84)
$ 30.8935%Reduce -78.32%56,118
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

IPXL is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


IPXL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SCHLOSSBERG MARK ASVP and General Counsel 2015-09-11Sell7,457$43.3-28.66view
NESTOR MICHAELPresident, Impax Pharm. 2015-09-10Sell5,000$43.56-29.09view
FLEMING NIGELDirector 2015-08-31Sell29,166$41.02-24.7view
MARKBREITER MICHAELDirector 2015-08-31Sell28,000$41.7-25.92view
BENET LESLIE ZDirector 2015-08-31Sell20,000$40.92-24.51view
SCHLOSSBERG MARK ASVP and General Counsel 2015-08-27Sell4,649$43.41-28.84view
TERRERI PETER RDirector 2015-08-27Sell4,833$43.93-29.68view
MARKBREITER MICHAELDirector 2015-08-26Sell19,399$42.24-26.87view
HSU LARRYDirector 2014-06-06Sell100,000$28.388.84view
TERRERI PETER RDirector 2014-05-27Sell3,000$2810.32view

Quarterly/Annual Reports about IPXL:

    News about IPXL:

    Articles On GuruFocus.com
    Alan Fournier Makes Modest Reductions in Middleby and Priceline Jan 12 2016 
    Allergan Among Health Care Holdings in Alan Fournier's Portfolio Dec 15 2015 
    Pharmaceutical Stocks Hold Prominent Positions in Kyle Bass' 3rd-Quarter Activity Nov 27 2015 
    Kyle Bass Goes Fishing for These 3 New Holdings Nov 26 2015 
    Alan Fournier's Highest Performing Stocks Jul 15 2015 
    Alan Fournier's Most Heavily Weighted Trades In Q1 2015 May 28 2015 
    Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
    President and CEO of Impax Laboratories Inc. (IPXL) Larry Hsu Bought 10,000 Shares Aug 17 2011 
    Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 5,000 Shares Aug 12 2010 
    Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 10,000 Shares Aug 12 2010 

    More From Other Websites
    Healthcare Trade Setups to Win -- Teva Pharma Industries, Endo Intl., Impax Laboratories, and... Feb 12 2016
    Impax Receives Tentative FDA Approval for Generic Version of Vytorin® (ezetimibe and simvastatin)... Feb 02 2016
    Impax to Report Fourth Quarter and Full Year 2015 Results on February 22, 2016 Jan 21 2016
    Impax to Report Fourth Quarter and Full Year 2015 Results on February 22, 2016 Jan 21 2016
    Impax's Emverm Approved for Parasitic Worm Infestations Jan 19 2016
    Impax Receives Approval of EMVERM™ (mebendazole) Chewable Tablets, 100 mg Jan 15 2016
    IMPAX LABORATORIES INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 12 2016
    Impax Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : January 8, 2016 Jan 08 2016
    Impax to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 05 2016
    New Year’s stock picks Dec 30 2015
    IMPAX LABORATORIES INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Dec 09 2015
    IMPAX LABORATORIES INC Financials Dec 08 2015
    Do Hedge Funds Love Impax Laboratories Inc (IPXL)? Dec 01 2015
    New Additions Highlight Billionaire Kyle Bass’ Top Stock Picks for Q4 Dec 01 2015
    Hedge Funds Are Buying HomeAway, Inc. (AWAY) Dec 01 2015
    Impax Laboratories, Inc. Earnings Q3, 2015 Nov 30 2015
    Pra Group Inc (PRAA): Are Hedge Funds Right About This Stock? Nov 29 2015
    Impax's Parkinson's Disease Drug Numient Approved in EU Nov 26 2015
    Impax Receives European Commission Marketing Authorization for NUMIENT™ (Levodopa and Carbidopa)... Nov 25 2015
    Impax Launches Generic Version of Avodart® (Dutasteride) Capsules, 0.5 mg Nov 24 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK